NEWSROOM

PRESS RELEASES

March 28, 2022
Aristea Therapeutics Announces Dosing of First Patient in Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis

SAN DIEGO, March 28, 2022 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced the dosing of the first patient in its Phase 2b trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of palmoplantar pustulosis (PPP), a rare inflammatory skin disorder. read more →

January 14, 2022
Aristea Therapeutics Announces Key Leadership Appointments to Advance its Clinical Pipeline

SAN DIEGO, Jan. 13, 2022 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat rare serious inflammatory diseases, today announced the appointment of Ciara Kennedy as Aristea Therapeutics' Chair of the Board of Directors and Fabio Magrini as Executive Medical Director. read more →

IN THE NEWS

Two Disabled Dudes Podcast

May 15, 2022
Doing the Right Thing with James Mackay, CEO Aristea Tx

James Mackay, PhD, Founder, President and Chief Executive Officer of Aristea Therapeutics, has over 25 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. James joins The Dudes to discuss his experience and how he is contributing to the biotech leadership community. read more →

BioSpace

April 4, 2022
Clinical Catch-Up: Adagio to Seek COVID-19 EUA, CytoDyn’s Bad Week

It was a particularly busy week for clinical trial announcements. read more →

EVENTS

2nd Annual Symposium for Inflammatory Skin Diseases Virtual
June 10, 2022

Aristea will be sponsoring and exhibiting at the 2nd Annual Symposium for Inflammatory Skin Diseases Virtual. read more →

BIO Partnering Meeting
June 13, 2022

Aristea participating at BIO Partnering Meeting. read more →

PRESENTATIONS